SPRUCE BIOSCIENCES INC (SPRB)

Company Profile

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 22 full-time employees. The company went IPO on 2020-10-09. The firm is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The company is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). The company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. The company has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The firm also investigates tildacerfont for the treatment of classic CAH in children.

Company Info

SPRUCE BIOSCIENCES INC

611 Gateway Boulevard, Suite 740

South San Francisco CALIFORNIA 94104

P: 14156554168

CEO: Richard King

Employees: 22

Website: https://sprucebio.com/